Eyepoint Pharmaceuticals has appointed Michael Campbell as Chief Commercial Officer (CCO) to enhance its product offerings and market presence. Campbell brings over 30 years of commercial leadership experience and a strong background in successful product launches. His role will be crucial in the company’s aim to deliver the first sustained-release TKI to patients.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Eyepoint Pharmaceuticals appoints Campbell to boost product launches
Eyepoint Pharmaceuticals has appointed Michael Campbell as Chief Commercial Officer (CCO) to enhance its product offerings and market presence. Campbell brings over 30 years of commercial leadership experience and a strong background in successful product launches. His role will be crucial in the company’s aim to deliver the first sustained-release TKI to patients.